Search results for "Growth factor"

showing 10 items of 1300 documents

Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exe…

2005

Aim: The aim of this study was to investigate the role of skeletal muscle fibre type in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance (IGT) during a 2-year exercise anddietary intervention. Methods: Muscle biopsies (musculus vastus lateralis) were taken from 22 subjects belonging to the intervention group of the Finnish Diabetes Prevention Study [1]. According to their myosin heavy chain (MHC) profile at the baseline, the subjects were divided into two groups: IGT s l o w (n = 10) with a high proportion of MHC I isoforms and IGT f a s t (n = 12) with a high proportion of MHC II isoforms in the vastus lateralis muscle. The intervention con…

AdultBlood GlucoseMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiet Reducingendocrine system diseasesVastus lateralis muscleEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalCarbohydrate metabolismImpaired glucose toleranceGlycogen Synthase Kinase 3EndocrinologyInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceWeight LossInternal MedicinemedicineHumansAerobic exerciseObesityMuscle SkeletalGlycogen synthaseExerciseAgedMyosin Heavy Chainsbiologybusiness.industrynutritional and metabolic diseasesSkeletal muscleMiddle Agedmedicine.diseaseCombined Modality Therapymedicine.anatomical_structureEndocrinologybiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsFollow-Up StudiesDiabetes, Obesity and Metabolism
researchProduct

Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study.

2012

To evaluate the metabolic effects of first-line somatostatin analogues or surgery in acromegaly. Retrospective, comparative, 12-month follow-up. Two hundred and thirty one patients (123 men, age 47.32 ± 14.63 years) with active acromegaly, first line treatments were somatostatin analogues in 151 (65.4%) and surgery in 80 (34.6%). Metabolic syndrome (MS) parameters, glucose, insulin and GH during oral glucose tolerance test, stimulated insulin sensitivity by insulin sensitivity index (ISI Matsuda), early and total insulin-secretion rate by insulinogenic index and AUC(INS), visceral adiposity function, expressed by visceral adipose index (VAI). Somatostatin analogues treatment improved all MS…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentsomatostatin analogueSettore MED/13 - EndocrinologiasurgeryYoung AdultEndocrinologyInternal medicineAcromegalyMedicineHumansYoung adultInsulin-Like Growth Factor IAgedRetrospective StudiesAged 80 and overbusiness.industryHuman Growth HormoneInsulinRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryFirst line treatmentSomatostatinEndocrinologyMetabolic effectsAcromegalyacromegaly; somatostatin analogues; metabolismFemaleMetabolic syndromebusinessSomatostatinmetabolismPituitary
researchProduct

Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation.

2006

Three commercial systems for whole blood separation were compared to obtain the buffy coat composed of platelet-rich plasma (BC-PRP) and leucocytes . These samples of the buffy coat were used to make a platelet gel (PG), which was used to measure platelet growth factor (PGF) release, to perform a white blood cell (WBC) count and to measure myeloperoxidase (MPO) release from WBCs. Aliquots of whole blood obtained from ten volunteers were distributed either to a blood cell separator (The Electa Cell-Separator (TM), E-CS) or to a tabletop centrifuge (Gravitational Platelet Sequestration System (TM), GPS) to prepare the BC-PRP. The third system combines the BC-PRP production by E-CS with a micr…

AdultBlood PlateletsBuffy coatFibrin Tissue AdhesiveBlood cellTransforming Growth Factor beta1Blood Transfusion AutologousLeukocyte CountThrombinTransforming Growth Factor betaWhite blood cellmedicineLeukocytesHumansPlateletPlatelet activationWhole bloodPeroxidasePlatelet-Derived Growth FactorWound HealingChromatographybiologyChemistryHematologyPlatelet Activationmedicine.anatomical_structureBiochemistryMyeloperoxidasebiology.proteinBlood Component RemovalGelsmedicine.drugTransfusion medicine (Oxford, England)
researchProduct

Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count.

2002

Abstract Introduction: Platelet-rich plasma contains autologous thrombocyte growth factors and might be promising for acceleration of dentoalveolar bone regeneration. In this study, it was analysed for platelet counts and growth factor concentrations. Material and method: Platelet-rich plasma was isolated by discontinuous cell separation from 158 healthy men and 55 women aged 17–62 years. One hundred and fifteen specimens (stratified for age and gender of the donor) were analysed for growth factor concentrations and platelet count. Results: The platelet count in platelet-rich plasma (1,407,640±320,100/μl) was 5 times higher than in donor blood (266,040±60,530/μl). Platelet-derived growth fa…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorAdolescentmedicine.medical_treatmentBecaplerminPlateletpheresisBlood DonorsEnzyme-Linked Immunosorbent AssayTransforming Growth Factor beta1chemistry.chemical_compoundTransforming Growth Factor beta2Sex FactorsTransforming Growth Factor betaInternal medicineMedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesPlatelet-Derived Growth Factorbiologybusiness.industryPlatelet CountGrowth factorPlateletpheresisAge FactorsProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyOtorhinolaryngologychemistryPlatelet-rich plasmabiology.proteinSurgeryFemaleOral SurgerybusinessGelsPlatelet-derived growth factor receptorTransforming growth factorJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Quantification of thrombocyte growth factors in platelet concentrates produced by discontinuous cell separation.

2002

Platelet concentrates (PC) are increasingly used to increase bone regeneration in pre-prosthetic surgery. Although it is generally appreciated that certain growth factors (PDGF, TGF, EGF, and ECGF) are present in thrombocyte preparations, relatively little is known about these components in quantitative terms. The study reported here analysed the amounts of growth factors in PC produced under standard conditions from healthy volunteers. All the blood samples (237 in total) were analysed using Quantikine ELISA kits (R and D). The mean +/- SD platelet count in whole blood from these donors was 262,000+/-58,000/microl, while in PC produced by discontinuous cell separation it was 1.419,000+/-33…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet-derived growth factorTime Factorsmedicine.medical_treatmentClinical BiochemistryBecaplerminEnzyme-Linked Immunosorbent AssayCell SeparationTransforming Growth Factor beta1chemistry.chemical_compoundInsulin-like growth factorTransforming Growth Factor beta2EndocrinologySex FactorsTransforming Growth Factor betaInternal medicinemedicineHumansPlateletInsulin-Like Growth Factor IBone regenerationGrowth SubstancesWhole bloodAgedPlatelet-Derived Growth FactorChromatographybiologyChemistryGrowth factorCell BiologyProto-Oncogene Proteins c-sisMiddle AgedEndocrinologyPlatelet-rich plasmabiology.proteinFemalePlatelet-derived growth factor receptorGrowth factors (Chur, Switzerland)
researchProduct

Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients.

2017

Summary T helper 9 (Th9) cells and interleukin (IL)-9 are involved in the pathogenesis of several autoimmune diseases. The exact role of IL-9 and Th9 cells in patients with systemic sclerosis (SSc) have not yet been studied adequately. IL-9, IL-9R, transcription factor PU.1 (PU.1), IL-4, thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-β expression were assessed in skin and kidney biopsies of SSc patients and healthy controls (HC) by immunohistochemistry (IHC). The cellular source of IL-9 was also analysed by confocal microscopy analysis. Peripheral IL-9-producing cells were also studied by flow cytometry. The functional relevance of IL-9 increased expression in SSc …

AdultCD4-Positive T-LymphocytesMale0301 basic medicineIL-9 ILC2 systemic sclerosis Th9Thymic stromal lymphopoietinNeutrophilsImmunologyExtracellular TrapsPeripheral blood mononuclear cellFlow cytometryILC2Pathogenesis03 medical and health sciencesThymic Stromal LymphopoietinTransforming Growth Factor betaProto-Oncogene ProteinsmedicineHumansImmunology and AllergyTh9Interleukin 9Mast CellsAutoantibodiesSkinReceptors Interleukin-9B-LymphocytesScleroderma Systemicmedicine.diagnostic_testintegumentary systembusiness.industryInterleukin-9InterleukinCell DifferentiationOriginal ArticlesNeutrophil extracellular trapsMiddle AgedIL-9Settore MED/16 - Reumatologia030104 developmental biologyImmunologyTrans-ActivatorsCytokinesImmunohistochemistryFemaleInterleukin-4businesssystemic sclerosi
researchProduct

GARP inhibits allergic airway inflammation in a humanized mouse model

2016

Background Regulatory T cells (Treg) represent a promising target for novel treatment strategies in patients with inflammatory/allergic diseases. A soluble derivate of the Treg surface molecule glycoprotein A repetitions predominant (sGARP) has strong anti-inflammatory and regulatory effects on human cells in vitro as well as in vivo through de novo induction of peripheral Treg. The aim of this study was to investigate the immunomodulatory function of sGARP and its possible role as a new therapeutic option in allergic diseases using a humanized mouse model. Methods To analyze the therapeutic effects of sGARP, adult NOD/Scidγc−/− (NSG) mice received peripheral blood mononuclear cells (PBMC) …

AdultCD4-Positive T-LymphocytesMale0301 basic medicinehumanized animal modelImmunologyNodProtein Serine-Threonine Kinasespulmonary inflammationT-Lymphocytes RegulatoryPeripheral blood mononuclear cellregulatory T cellsAllergic inflammationMice03 medical and health sciences0302 clinical medicineImmune ToleranceRespiratory HypersensitivitymedicineAnimalsHumansImmunology and AllergyReceptorLungSensitizationInflammationtolerancebiologybusiness.industryReceptor Transforming Growth Factor-beta Type IIMembrane ProteinsPeripheral toleranceAllergensImmunoglobulin EMiddle AgedasthmaDisease Models Animal030104 developmental biologymedicine.anatomical_structure030228 respiratory systemHumanized mouseImmunologybiology.proteinFemaleAntibodybusinessReceptors Transforming Growth Factor betaAllergy
researchProduct

EGFR and PCNA experession in oral squamous cell carcinomas—a valuable tool in estimating the patient's prognosis

1993

We investigated 100 cases of oral squamous cell carcinomas immunohistologically with respect to the expression of the epidermal growth factor receptor (EGFR) and the proliferating cell nuclear antigen (PCNA). The results were correlated with a new malignancy grading of the invasive tumour areas and the clinical outcome of the patients to estimate the individual prognosis. In conclusion, the amount of antigen expression of both antigens increases with the increasing grade of malignancy of the oral squamous cell carcinoma. Furthermore, there is a statistically significant correlation between the amount of antigen expression and the patient's prognosis. An overexpression of EGFR and PCNA is as…

AdultCancer ResearchPathologymedicine.medical_specialtyMalignancyAntigenPredictive Value of TestsEpidermal growth factorProliferating Cell Nuclear AntigenBiomarkers TumormedicineHumansNeoplasm InvasivenessProspective StudiesEpidermal growth factor receptorSurvival analysisNeoplasm StagingMouth neoplasmbiologyPrognosismedicine.diseaseImmunohistochemistrySurvival AnalysisProliferating cell nuclear antigenErbB ReceptorsGene Expression Regulation Neoplasticstomatognathic diseasesTreatment OutcomeOncologyCarcinoma Squamous CellCancer researchbiology.proteinImmunohistochemistryMouth NeoplasmsEuropean Journal of Cancer Part B: Oral Oncology
researchProduct

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical…

2014

Abstract Purpose: Mammalian target of rapamycin (mTOR) inhibition activates compensatory insulin–like growth factor receptor (IGFR) signaling. We evaluated the ridaforolimus (mTOR inhibitor) and dalotuzumab (anti-IGF1R antibody) combination. Experimental Design: In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10–40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. Results: Preclinical studies demonstrated enhanced pathway inhibition with ridaforolimus and dalotuzumab. With 87 patients treated in the phase I study, main dose-limiting toxicities (DLT) of the combination were p…

AdultCancer ResearchPhases of clinical researchBreast NeoplasmsPharmacologyAntibodies Monoclonal HumanizedArticleReceptor IGF Type 1Ridaforolimuschemistry.chemical_compoundBreast cancerIn vivoAntineoplastic Combined Chemotherapy ProtocolsMedicineAnimalsHumansPI3K/AKT/mTOR pathwayInsulin-like growth factor 1 receptorAgedSirolimusDalotuzumabbusiness.industryTOR Serine-Threonine KinasesAntibodies MonoclonalReceptors SomatomedinMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysOncologychemistryMonoclonalbusinessSignal TransductionClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis

2022

The association between IGF-1 levels and mortality in humans is complex with low levels being associated with both low and high mortality. The present meta-analysis investigates this complex relationship between IGF-1 and all-cause mortality in prospective cohort studies. A systematic literature search was conducted in PubMed/MEDLINE, Scopus, and Cochrane Library up to September 2019. Published studies were eligible for the meta-analysis if they had a prospective cohort design, a hazard ratio (HR) and 95% confidence interval (CI) for two or more categories of IGF-1 and were conducted among adults. A random-effects model with a restricted maximum likelihood heterogeneity variance estimator w…

AdultCohort StudiesAgingIGF-1HumansCell BiologyProspective StudiesInsulin-Like Growth Factor Imortalityprotein intakeProportional Hazards Models
researchProduct